Transitional Care for Liver Disease
(TLC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a special program called the Transitional Liver Clinic (TLC) for patients with severe liver disease. The TLC aims to reduce hospital readmissions by offering extra support and care coordination after patients leave the hospital.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is transitional care for liver disease safe for humans?
Transitional care models, including those for liver disease, have been studied for their effectiveness in improving health outcomes and reducing hospital readmissions. While specific safety data for liver disease is not detailed, these models generally focus on improving care transitions, which can enhance patient safety by reducing medication errors and ensuring better continuity of care.12345
How is the Transitional Liver Clinic (TLC) treatment different from other treatments for liver disease?
The Transitional Liver Clinic (TLC) treatment is unique because it focuses on providing continuous care as patients move from the hospital to home, aiming to reduce complications and hospital readmissions. This approach is particularly important for young adults transitioning from pediatric to adult care, ensuring they receive consistent support and education to manage their health independently.26789
What data supports the effectiveness of the treatment Transitional Liver Clinic (TLC) and Transitional Care Model for liver disease?
Research suggests that attending a Transitional Liver Clinic (TLC) may help reduce hospital readmissions for patients with liver disease. Additionally, transitional care programs, which include follow-up after hospital discharge, have been shown to reduce hospitalizations and improve outcomes in various patient populations.24101112
Who Is on the Research Team?
Eric Orman, MD
Principal Investigator
Indiana University
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced liver disease, either cirrhosis or acute alcoholic hepatitis. Participants must have had a recent complication from their condition and be ready to leave the hospital soon. They need to speak English or Spanish, be able to follow up after discharge, and not be in hospice care or listed for a liver transplant with a high MELD-Na score.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Control Phase
Participants receive usual care during the initial 9-month enrollment interval
Transitional Liver Clinic (TLC) Phase
Participants receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit within 14 days of discharge. Additional care is provided based on individual patient needs during the 30-day transitional period.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Transitional Liver Clinic (TLC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Indiana University
Lead Sponsor
Eric Orman
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator